Status:
COMPLETED
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
Lead Sponsor:
University of Southern Denmark
Collaborating Sponsors:
Odense University Hospital
Conditions:
Adverse Drug Event
Colon Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to examine the benefits of a clinical implementation of a DPYD-genotype test to patients starting treatment with fluoropyrimidines (Fluorouracil (5-FU), capecitabine, tega...
Detailed Description
Patients with specific genetic mutations in the DPYD-gene have lower activity of the dihydropyrimidine dehydrogenase (DPD) enzyme, which is the rate-limiting enzyme in the metabolism of fluoropyrimidi...
Eligibility Criteria
Inclusion
- Patients with cancer that are eligible for systemic treatment with 5-FU, capecitabine, or tegafur.
Exclusion
- Patients that earlier have been treated with 5-FU, capecitabine, or tegafur
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2022
Estimated Enrollment :
722 Patients enrolled
Trial Details
Trial ID
NCT05266300
Start Date
September 1 2020
End Date
October 1 2022
Last Update
November 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Department of Oncology at University of southern denmark
Odense, Region Syddanmark, Denmark, 5000